taking rna therapeutics to the next level
At DIVINCELL, our goal is to improve the patient experience by developing more effective, faster, and more accessible cancer treatments.
We create the next-generation RNA therapeutics by combining engineered RNA with precision-designed targeting peptides—delivering breakthrough treatments that attack cancer, autoimmune, and genetic diseases at their source.
Our programs
DivinCell Inc harnesses engineered RNA molecules and proprietary targeting peptides (PEP-NPTM platform) to create groundbreaking therapies for cancer, autoimmune, and genetic diseases—enabling safe, repeated, and highly selective in vivo delivery of RNA agents.
Our technology
- Tumor Suppressor Restoration (TSG-RESCUETM) : Restoring the key tumor suppressors (p53) in cancers driven by loss-of-function mutations, for which there are currently no effective treatments.
- Oncogene Editing/Deletion (ONCOEDITTM) : Targeted deletion or silencing of oncogenic mutations (KRAS G12D/V/C), enabling direct treatment of cancers associated with oncogenes and overcoming resistance to current treatments.
- CAR-T in vivo (PEP-CARTM) : Transforming T cells within the body, revolutionizing anti-CD19 CAR-T therapy for blood cancers and autoimmune disease, minimizing toxicity and complexity for individuals with cancer or autoimmune diseases.
Divincell’s strategy is to deliver therapeutic RNAs directly to diseased cells using our proprietary PEP-NPTM peptide technology.
We leverage modified RNA molecules and proprietary targeting peptides to create groundbreaking therapies for cancer, autoimmune, and genetic diseases, enabling repeated and highly selective delivery of therapeutic RNAs.
Our versatile PEP-NPTM technology addresses the key challenge of RNA therapies: precise systemic targeting in vivo and efficient cellular delivery, paving the way for a new era of programmable molecular medicine.
Overcoming the Delivery Barrier
Unlike viral and lipid systems, our versatile PEP-NPTM technology surmounts the greatest challenge in RNA therapeutics: precise and safe systemic in vivo targeting and efficient cellular release—enabling a new era of programmable molecular medicine.
our team
Research and Development
Divincell draws on 25 years of experience in Nanomedicine and targeted drug delivery. Divincell was founded by industry and research leaders.
Dr Gilles Divita
Institut Max Planck, Scripps Research Institute, CNRS
A pioneer of peptide-driven oligonucleotide delivery
Dr Neil Desai
Abraxis, Celgene, Aadi Bioscience
A pioneer in albumin-based drug delivery
